IMMY Profile
Imprimis
Pharmaceuticals, Inc. (IMMY) is a specialty pharmaceutical company
focused on developing, manufacturing, and selling novel and customized
compounded drug formulations. The company’s product portfolio includes
compounded drugs for ophthalmology, urology, pain management, and
other therapeutic areas.
One of the company’s most notable
products is its compounded formulation of pyrimethamine and
leucovorin, which is used to treat toxoplasmosis, a parasitic
infection that can cause blindness and other serious health problems.
This formulation gained attention in 2015 when Turing Pharmaceuticals,
under the leadership of Martin Shkreli, raised the price of the only
FDA-approved pyrimethamine drug from $13.50 to $750 per tablet.
Imprimis responded by creating a more affordable compounded version of
the drug, which sparked controversy and highlighted the issue of high
drug prices in the U.S.
In addition to its compounded drug
formulations, Imprimis also has a drug development pipeline focused on
oncology and ophthalmology. The company is developing a proprietary
drug delivery technology platform, known as Accudel, which is designed
to enhance the effectiveness and safety of injectable drugs.
Imprimis Pharmaceuticals was founded in 1998 and is headquartered in
San Diego, California. The company’s stock is traded on the Nasdaq
Global Market under the ticker sym
|
